Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-028189
Filing Date
2021-05-17
Accepted
2021-05-17 08:00:39
Documents
66
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q vcnx-10q_20210331.htm 10-Q 1263790
2 EX-31.1 vcnx-ex311_59.htm EX-31.1 21224
3 EX-31.2 vcnx-ex312_60.htm EX-31.2 20897
4 EX-32.1 vcnx-ex321_61.htm EX-32.1 10847
  Complete submission text file 0001564590-21-028189.txt   4929235

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT vcnx-20210331.xml EX-101.INS 869173
6 XBRL TAXONOMY EXTENSION SCHEMA vcnx-20210331.xsd EX-101.SCH 50053
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vcnx-20210331_cal.xml EX-101.CAL 32824
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vcnx-20210331_def.xml EX-101.DEF 165925
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE vcnx-20210331_lab.xml EX-101.LAB 375401
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vcnx-20210331_pre.xml EX-101.PRE 291148
Mailing Address 1895 MOUNT HOPE AVE ROCHESTER NY 14620
Business Address 1895 MOUNT HOPE AVE ROCHESTER NY 14620 585-271-2700
VACCINEX, INC. (Filer) CIK: 0001205922 (see all company filings)

EIN.: 161603202 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38624 | Film No.: 21927650
SIC: 2834 Pharmaceutical Preparations